CSIMarket Company Name, Ticker, Competitors, else..
 
Relay Therapeutics Inc   (NASDAQ: RLAY)
 
Price: $18.9100 $0.02 0.106%
Day's High: $19.350000381469727 Week Perf: -0.68 %
Day's Low: $ 18.82 30 Day Perf: -5.78 %
Volume (M): 376,284 52 Wk High: $ 21.27
Volume (M$): $ 0 52 Wk Avg: $11.77
Open: $19.17 52 Wk Low: $3.88



 Market Capitalization (Millions $) 3,836
 Shares Outstanding (Millions) 203
 Employees 192
 Revenues (TTM) (Millions $) 10
 Net Income (TTM) (Millions $) -286
 Cash Flow (TTM) (Millions $) 90
 Capital Exp. (TTM) (Millions $) 0

Business Description


Relay Therapeutics Inc is a biotechnology company that focuses on developing new treatments for cancer and other diseases. The company uses a combination of computation, experimental biology, and medicinal chemistry to discover and design potential therapies. Their approach involves studying the movement and interaction of proteins within cells to identify targets for drug development. By understanding how proteins behave, Relay Therapeutics aims to create precise and effective therapies that can address the underlying causes of diseases. The company's goal is to deliver breakthrough treatments and improve patients' lives.


   Company Address: 60 Hampshire Street Cambridge 2139 MA
   Company Phone Number: 370-8837   Stock Exchange / Ticker: NASDAQ RLAY


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
BCRX   -18.73%    
BEAM   -17.41%    
CCCC   -9.36%    
DNA   -4.24%    
KRYS   -6.23%    
RGNX   -7.83%    
• View Complete Report
   



Product Service News

Relay Therapeutics Reports Promising Interim Data for RLY-2608 in Advanced Breast Cancer A Step Forward in Targeted T...

Published Mon, Dec 30 2024 2:44 AM UTC

In the evolving landscape of oncology therapies, Relay Therapeutics has announced notable updates regarding its investigational drug, RLY-2608, in combination with fulvestrant for the treatment of patients with PI3K-mutated, hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) metastatic breast cancer. The company’s recent interim data...
Clinical Study

Promising Interim Data on RLY-2608 A Breakthrough in Progression-Free Survival by Relay Therapeutics

Published Mon, Sep 9 2024 10:55 AM UTC

In a pivotal moment for precision oncology, Relay Therapeutics Inc. (NASDAQ: RLAY) has announced encouraging interim data from its ongoing trial of RLY-2608, a targeted therapy designed for patients with advanced solid tumors. The findings signal a potential step forward in the quest for more effective cancer treatments, particularly in terms of improving progression-free su...
Clinical Study

Upcoming Webcast by Relay Therapeutics Insights into RLY-2608 Data on September 9, 2024

Published Fri, Sep 6 2024 8:06 PM UTC

: Relay Therapeutics has announced a webcast slated for September 9, 2024, during which the company will share crucial data regarding its investigational drug RLY-2608. This article examines the significance of this upcoming event within the context of drug development, particularly in precision medicine and oncology. Relay Therapeutics, a biotechnology company at the for...
Clinical Study

Relay Therapeutics and Pfizer Join Forces in Trailblazing Clinical Trial to Combat Aggressive Breast Cancer Subtypeb...

Published Wed, Jun 5 2024 8:05 PM UTC

Relay Therapeutics and Pfizer Collaborate on Groundbreaking Clinical Trial for PI3K-Mutated HR+/HER2- Metastatic Breast CancerIn an exciting development in the fight against metastatic breast cancer, Relay Therapeutics has announced a clinical trial collaboration with pharmaceutical giant Pfizer. This joint effort aims to explore the potential benefits of combining Atirmoci...



Fundamental Analysis

Valuation Current
Price to Earnings PE Ratio (TTM) -
Price to Earnings PE Ratio (Expected) -
Price to Sales (TTM) 370.65
Price to Sales (Expected) -
Price to Book 4.31
PEG (TTM) -

Financial Strength Current
Quick Ratio 17.93
Working Capital Ratio 18.27
Leverage Ratio (MRQ) 0.09
Total Debt to Equity -
Interest Coverage (TTM) -
Debt Coverage (TTM) -

Per Share Current
Earnings (TTM) -1.57 $
Revenues (TTM) 0.05 $
Cash Flow (TTM) 0.44 $
Cash 4.49 $
Book Value 4.39 $
Dividend (TTM) 0 $

Efficiency Current
Revenue per Employee (TTM) 53,901
Net Income per Employee (TTM) -1,489,776
Receivable Turnover Ratio (TTM) -
Inventory Turnover Ratio (TTM) -
Asset Turnover Ratio (TTM) 0.01

Profitability Ratios Current
Gross Margin (MRQ) 0 %
Operating Margin (MRQ) -25949.71 %
Net Margin (MRQ) -23916.29 %
Net Cash Flow Margin (MRQ) 0 %
Effective Tax Rate (TTM) -

Management Effectiveness Current
Return On Assets (TTM) -
Return On Investment (TTM) -
Return On Equity (TTM) -
Dividend Yield -
Pay out Ratio (TTM) -



Relay Therapeutics Inc's Segments
Revenue Abstract    957.14 % of total Revenue





Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.